Literature DB >> 34561810

Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.

Roy Fleischmann1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34561810     DOI： 10.1007/s10067-021-05933-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  24 in total

1.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Authors:  Peter C Taylor; Edward C Keystone; Désirée van der Heijde; Michael E Weinblatt; Liliana Del Carmen Morales; Jaime Reyes Gonzaga; Sergey Yakushin; Taeko Ishii; Kahaku Emoto; Scott Beattie; Vipin Arora; Carol Gaich; Terence Rooney; Douglas Schlichting; William L Macias; Stephanie de Bono; Yoshiya Tanaka
Journal:  N Engl J Med       Date:  2017-02-16       Impact factor: 91.245

Review 2.  Network meta-analysis for comparing treatment effects of multiple interventions: an introduction.

Authors:  Ferrán Catalá-López; Aurelio Tobías; Chris Cameron; David Moher; Brian Hutton
Journal:  Rheumatol Int       Date:  2014-04-02       Impact factor: 2.631

3.  How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

Authors:  Roy Fleischmann; Désirée van der Heijde; Andrew S Koenig; Ronald Pedersen; Annette Szumski; Lisa Marshall; Eustratios Bananis
Journal:  Ann Rheum Dis       Date:  2014-08-20       Impact factor: 19.103

4.  Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Authors:  Roy Fleischmann; Eduardo Mysler; Stephen Hall; Alan J Kivitz; Robert J Moots; Zhen Luo; Ryan DeMasi; Koshika Soma; Richard Zhang; Liza Takiya; Svitlana Tatulych; Christopher Mojcik; Sriram Krishnaswami; Sujatha Menon; Josef S Smolen
Journal:  Lancet       Date:  2017-06-16       Impact factor: 79.321

5.  Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.

Authors:  Roy Fleischmann; Aileen L Pangan; In-Ho Song; Eduardo Mysler; Louis Bessette; Charles Peterfy; Patrick Durez; Andrew J Ostor; Yihan Li; Yijie Zhou; Ahmed A Othman; Mark C Genovese
Journal:  Arthritis Rheumatol       Date:  2019-08-28       Impact factor: 10.995

6.  Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.

Authors:  Andrea Rubbert-Roth; Jeffrey Enejosa; Aileen L Pangan; Boulos Haraoui; Maureen Rischmueller; Nasser Khan; Ying Zhang; Naomi Martin; Ricardo M Xavier
Journal:  N Engl J Med       Date:  2020-10-15       Impact factor: 91.245

Review 7.  Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.

Authors:  Aimee Kendall Roundtree; Michael A Kallen; Maria A Lopez-Olivo; Barbara Kimmel; Becky Skidmore; Zulma Ortiz; Vanessa Cox; Maria E Suarez-Almazor
Journal:  J Clin Epidemiol       Date:  2008-11-14       Impact factor: 6.437

8.  Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

Authors:  Bernard Combe; Alan Kivitz; Yoshiya Tanaka; Désirée van der Heijde; J Abraham Simon; Herbert S B Baraf; Uma Kumar; Franziska Matzkies; Beatrix Bartok; Lei Ye; Ying Guo; Chantal Tasset; John S Sundy; Angelika Jahreis; Mark C Genovese; Neelufar Mozaffarian; Robert B M Landewé; Sang-Cheol Bae; Edward C Keystone; Peter Nash
Journal:  Ann Rheum Dis       Date:  2021-01-27       Impact factor: 19.103

9.  Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Authors:  Edward C Keystone; Peter C Taylor; Yoshiya Tanaka; Carol Gaich; Amy M DeLozier; Anna Dudek; Jorge Velasco Zamora; Jose Arturo Covarrubias Cobos; Terence Rooney; Stephanie de Bono; Vipin Arora; Bruno Linetzky; Michael E Weinblatt
Journal:  Ann Rheum Dis       Date:  2017-08-10       Impact factor: 19.103

10.  Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.

Authors:  Josef Smolen; Roy Fleischmann; Daniel Aletaha; Yihan Li; Yijie Zhou; Iain Sainsbury; Ivan Lagunes Galindo
Journal:  Arthritis Res Ther       Date:  2019-11-10       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.